FDA Approves Delafloxacin for Treatment of Community-Acquired Bacterial Pneumonia
October 25th 2019The supplemental new drug application was approved based on results of a phase 3 trial in which IV-to-oral delafloxacin met the primary end point of statistical non-inferiority to moxifloxacin.
Read More
FDA Advisory Committee Backs Cefiderocol Efficacy for cUTI 14-2
October 17th 2019The committee voted 14 to 2 that substantial evidence of efficacy and safety for cefiderocol was provided for the treatment of cUTI including pyelonephritis in patients with limited or no alternative treatment options.
Read More
Contagion® Connect Episode 3: Can AI Cut Antimicrobial Resistance?
October 16th 2019Paul Abrams, MBA, director of Health Care Specialty Group at MJH Life Sciences, spoke to Vaibhav Singh from Circle of Life about Zevac, a tool that aims to help clinicians make more informed prescribing decisions.
Read More